Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719430 · ClinicalTrials.gov registry record · Phase 2
APX005M and Doxorubicin in Advanced Sarcoma
A Phase 2 study of Soft Tissue Sarcoma, sponsored by Alexander Z. Wei, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT03719430 is a Phase 2 study of Soft Tissue Sarcoma that is active but no longer recruiting, run by Alexander Z. Wei, MD. The registered enrollment target is 27 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03719430, a Phase 2 study of Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by Alexander Z. Wei, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG APX005M
Study Locations (3)
California
- City of Hope - Duarte
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
New York
- Columbia University Irving Medical Center/NYP - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719430
The ClinicalTrials.gov registry entry for NCT03719430 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (65% lower). The listed sponsor is Alexander Z. Wei, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Doxorubicin is the first listed.
NCT03719430 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT03719430 about?
NCT03719430 is a clinical study titled "APX005M and Doxorubicin in Advanced Sarcoma". This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most adv...
What is the current status of trial NCT03719430?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2019-03-20. Estimated completion is 2026-12-31.
What conditions does trial NCT03719430 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT03719430?
The interventions under investigation include: Doxorubicin (DRUG), APX005M (DRUG).
Who is sponsoring clinical trial NCT03719430?
This trial is sponsored by Alexander Z. Wei, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03719430 being conducted?
This trial has 3 study locations across California, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.